Deep Vein Thrombosis, Pulmonary Embolus Clinical Trial
Official title:
Inferior Vena Cava Filters Utilization in Patients With Venous Thromboembolism: Analysis of a Database of a Tertiary Hospital
In this study a retrospective analysis of patients database was performed, who underwent treatment for deep vein thrombosis in tertiary hospital by using inferior vena cava-filters
The aim of this research was to assess the cava-filter implantation frequency in a tertiary
hospital with venous thromboembolism treatment center.
A retrospective analysis of patient's database was performed, who underwent treatment in the
tertiary clinic between 2016 - 2017. In total, 2399 patients with venous thromboembolism were
hospitalized, 442 cava-filters were implanted (239 in 2016 and 203 in 2017), which accounted
for 18.4% of patients with venous thromboembolism. Removable cava-filters models were used in
most cases (98.8%). Contraindications for anticoagulation were reason for cava-filters
implantation in 119 (26.9%) cases, and in 184 patients (41.6%) cava-filters were implanted
due to the inefficiency of anticoagulation. 38 (8.6%) patients with deep vein thrombosis
(DVT) and pulmonary embolism had pulmonary hypertension of the 2nd to 3rd degree, which
caused the implantation of cava-filters .
The occlusion of the inferior vena cava and cava-filters verified in 116 (26.9%) patients
after cava-filters implantation, based on repeated ultrasound. The overall mortality rate in
the group of patients with venous thromboembolism was 0.25% (6 patients), 5 of them (1.1%)
underwent cava-filters implantation. The cause of all lethal outcomes was the progression of
the underlying disease. During the next hospitalization 29 (6.5%) of implanted filters were
endovascularly removed.
There are 18.4% of patients with venous thromboembolism undergoing cava-filters implantation
for various reasons in a tertiary hospital. At the same time, occlusion of the inferior vena
cava and cava-filters in the early post implantation period is observed in 26.9%. However,
without clear criteria for the differentiation of cava-filters embolism from its thrombosis,
we cannot assess whether this was a complication, or if the cava-filters completed its task
by preventing pulmonary embolism. Thus, the validity of implanting cava filters question in
terms of efficiency and safety remains unanswered, which poses the task for deep study of
this problem and thorough analysis of the indications for the cava-filters implantation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05083455 -
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
|
||
| Completed |
NCT06009484 -
VTE Incidence After Curative Colon Cancer Surgery in an ERAS Program
|